2022
A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System
Wang K, Deng Y, Stewart D, Formica R. A Composite End Point of Graft Status and eGFR at 1 Year to Improve the Scientific Registry of Transplant Recipients’ Five-Tier Rating System. Journal Of The American Society Of Nephrology 2022, 33: 1613-1624. PMID: 35537779, PMCID: PMC9342646, DOI: 10.1681/asn.2022010078.Peer-Reviewed Original ResearchConceptsComposite end pointTraditional end pointsTransplant programsEnd pointAllograft functionGraft survivalScientific RegistryFive-tier systemLong-term graft outcomeDonor graft survivalKidney transplant programAllograft failureAllograft survivalGraft outcomeTransplant recipientsGraft statusGraft failureEGFR differenceSRTR dataSurvival rateEGFRSurvivalRegistryMeaningful differencesConcept study
2019
Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era
Kadatz M, Gill JS, Gill J, Formica RN, Klarenbach S. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era. Journal Of The American Society Of Nephrology 2019, 31: 218-228. PMID: 31704739, PMCID: PMC6934999, DOI: 10.1681/asn.2019070646.Peer-Reviewed Original ResearchConceptsKidney transplant recipientsQuality-adjusted life yearsTransplant recipientsTransplant survivalDrug coverageMedicare coverageTransplant failureImmunosuppressant drugsAdditional quality-adjusted life yearCohort of MedicareMultivariable survival analysisIncremental cost-utility ratioBetter patient outcomesCost-utility ratioImmunosuppressant medicationsTransplant functionImmunosuppressive drugsPatient outcomesMedicare payersSurvival analysisLife yearsIncremental costRecipientsSurvivalDrugs